Kraj: Unia Europejska
Język: angielski
Źródło: EMA (European Medicines Agency)
autologous cultured chondrocytes
Vericel Denmark ApS
M09AX02
matrix-applied characterised autologous cultured chondrocytes
Other drugs for disorders of the musculo-skeletal system
Fractures, Cartilage
Repair of symptomatic cartilage defects of the knee.
Revision: 4
Withdrawn
2013-06-27
21 B. PACKAGE LEAFLET Medicinal product no longer authorised 22 PACKAGE LEAFLET: INFORMATION FOR THE USER MACI 500,000 TO 1,000,000 CELLS/CM 2 FOR IMPLANTATION Matrix applied characterised autologous cultured chondrocytes This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects. READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor, surgeon or physical therapist. • If you get any side effects talk to your doctor, surgeon or physical therapist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What MACI is and what it is used for 2. What you need to know before you use MACI 3. How to use MACI 4. Possible side effects 5. How to store MACI 6. Contents of the pack and other information 1. WHAT MACI IS AND WHAT IT IS USED FOR MACI is used in adults to repair cartilage defects in your knee joint. Cartilage is a tissue that is present in every joint in the body; it protects the ends of bones and allows joints to function smoothly. MACI is an implant consisting of a porcine derived (derived from pigs) collagen membrane which contains your own cartilage cells (called autologous chondrocytes) and is implanted into your knee. “Autologous” means that your own cells are used which have been taken from your knee (through a biopsy) and grown outside the body. 2. WHAT YOU NEED TO KNOW BEFORE YOU USE MACI DO NOT USE MACI IF YOU: • are allergic to any of the ingredients of MACI (listed in section 6), or porcine products (derived from pigs), bovine serum (a protein derived from cows) or gentamicin (an antibiotic) • have severe osteoarthritis of the knee (disease of the joints with pain and swelling) • currently suffer f Przeczytaj cały dokument
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS Medicinal product no longer authorised 2 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT MACI 500,000 to 1,000,000 cells/cm 2 implantation matrix 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each implant contains matrix applied characterised autologous cultured chondrocytes. 2.1 GENERAL DESCRIPTION Characterised viable autologous chondrocytes expanded _ex vivo _expressing chondrocyte-specific marker genes, seeded onto a CE marked porcine derived Type I/III collagen membrane. 2.2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each implantation matrix consists of characterised autologous chondrocytes on a 14.5 cm² Type I/III collagen membrane, at a density of 500,000 to 1,000,000 cells per cm 2 , to be trimmed by the surgeon to the size and shape of the defect. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Implantation matrix. The implant is an opaque, off-white membrane, seeded with chondrocytes, supplied in 18 ml of colourless solution in a dish. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS MACI is indicated for the repair of symptomatic, full-thickness cartilage defects of the knee (grade III and IV of the Modified Outerbridge Scale) of 3-20 cm 2 in skeletally mature adult patients. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION MACI is intended for autologous use only. MACI must be administered by a surgeon specifically trained and qualified in the use of MACI. Medicinal product no longer authorised 3 Posology The amount of MACI administered is dependent upon the size (surface in cm 2 ) of the cartilage defect. The implantation matrix is trimmed by the treating surgeon to the size and shape of the defect, to ensure the damaged area is completely covered, and implanted cell-side down. The administered dose cor Przeczytaj cały dokument